LIFE HEALTHCARE GROUP HOLDINGS UNSPON ADR EA REPR 4 ORD ZAR0.00
LTGHY
DOMINOS PIZZA ENTERPRISES LIMITED UNSP ADR EACH REPR 0.5 ORD SHS
DMZPY
New Fortress Energy
NFE
4
Hutchmed (China)
HCM
5
Lantheus
LNTH
US Stock MarketDetailed Quotes
PYXS Pyxis Oncology
- 1.030
- -0.030-2.83%
Trading Apr 28 14:33 ET
63.44MMarket Cap-0.78P/E (TTM)
1.090High1.020Low258.13KVolume1.080Open1.060Pre Close272.03KTurnover0.58%Turnover RatioLossP/E (Static)61.59MShares5.39052wk High0.53P/B45.67MFloat Cap0.83352wk Low--Dividend TTM44.34MShs Float19.000Historical High--Div YieldTTM6.60%Amplitude0.833Historical Low1.053Avg Price1Lot Size
Pyxis Oncology News
William Blair Sticks to Their Hold Rating for Pyxis Oncology (PYXS)
Pyxis Oncology Highlights Promising Preclinical Data for Micvotabart Pelidotin (MICVO) in Cancer Therapy at AACR 2025
Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC
Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
Pyxis Oncology to Present Preclinical Data for Micvo Cancer Drug Candidate
Pyxis Oncology Will Present New Preclinical Data Supporting Development Of First-In-Concept Antibody-Drug Conjugate Targeting EDB+FN In Tumor Microenvironment At AACR 2025
Express News | Pyxis Oncology To Present Preclinical Data On Potential Of PYX-201 At AACR 2025, Apr. 28
Pyxis Oncology Highlights Strategic Focus on Lead Candidate
Jefferies Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Cuts Target Price to $6
Citi Initiates Pyxis Oncology(PYXS.US) With Buy Rating, Announces Target Price $5
LifeSci Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating
Pyxis Oncology Price Target Maintained With a $8.00/Share by RBC Capital
Promising Clinical Developments and Strategic Focus Drive Buy Rating for Pyxis Oncology
HC Wainwright & Co. Reiterates Buy on Pyxis Oncology, Maintains $5 Price Target
Pyxis Oncology Analyst Ratings
Pyxis Oncology Advances Cancer Therapeutics With MICVO
Express News | Pyxis Oncology Inc : Jefferies Cuts Target Price to $6 From $12
William Blair Maintains Pyxis Oncology(PYXS.US) With Hold Rating
Pyxis Oncology (PYXS) Gets a Hold From William Blair
Pyxis Oncology Announces CMO Resignation and New Trials
Market Insights
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call